# US 2025/0082747 A1 · Porcine coronavirus vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082747 A1
- Document ID: US20250082747A1
- Status: Published application
- Kind: A1
- Application number: 18/893,431
- Filed: 2024-09-23
- Published: 2025-03-13
- Earliest claimed: 2017-01-30
- Assignees: Boehringer Ingelheim Animal Health USA Inc.
- Applicants: Boehringer Ingelheim Animal Health USA Inc.
- Inventors: Scott ACKERMAN; Joseph Ralph HERMANN; Luis Alejandro HERNANDEZ; Lea Ann HOBBS; Arun V. IYER; Sean O'CONNER; Abby Rae PATTERSON; Eric Martin VAUGHN; Joseph Gilbert VICTORIA
- Web page: https://patentgrep.com/patent/US20250082747A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/14043: viral genome or elements thereof as genetic vectore
- C12N 2710/14071: Demonstrated in vivo effect
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.

## Claims

### Claim 1

An immunogenic composition comprising an antigen of a porcine epidemic diarrhea virus (PEDV) and an adjuvant, wherein the PEDV comprises: (i) a polynucleotide having at least 99% sequence identity to SEQ ID NO: 32 or 36; (ii) a polynucleotide having at least 99% sequence identity to a RNA complement of SEQ ID NO: 29 or 33; and/or (iii) a spike protein encoded by a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 30, 34, 46, or 52.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the antigen is a chemically inactivated whole PEDV.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the antigen is a whole PEDV chemically inactivated with ethylenimine, binary ethylenimine, acetylethylenimine, or any combinations thereof.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein the antigen is a recombinant antigen.

### Claim 5 (depends on 4)

The immunogenic composition of claim 4, wherein the recombinant antigen comprises:
(i) a PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53; and/or (ii) a polynucleotide encoding the PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53.

### Claim 6 (depends on 4)

The immunogenic composition of claim 4, wherein the recombinant antigen comprises a M, E, or N protein of PEDV.

### Claim 7 (depends on 4)

The immunogenic composition of claim 4, wherein the recombinant antigen is a recombinant vector, a recombinant PEDV spike protein, or a combination thereof.

### Claim 8 (depends on 1)

The immunogenic composition of claim 1, wherein the adjuvant is an oil-in-water emulsion.

### Claim 9 (depends on 1)

The immunogenic composition of claim 1, further comprising a pharmaceutically acceptable carrier and/or an excipient.

### Claim 10 (depends on 1)

The immunogenic composition of claim 1, further comprising an antigen of a porcine Deltacoronavirus (PDCoV).

### Claim 11 (depends on 10)

The immunogenic composition of claim 10, wherein the PDCoV comprises: (i) a polynucleotide having at least 99% sequence identity to SEQ ID NO: 2, 6, or 10; (ii) a polynucleotide having at least 99% sequence identity to a RNA complement of SEQ ID NO: 1, 5, or 9; and/or (iii) a spike protein encoded by a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 3, 7, 11, 17, or 27.

### Claim 12 (depends on 11)

The immunogenic composition of claim 11, wherein the antigen of the PDCoV is an inactivated whole PDCoV.

### Claim 13 (depends on 11)

The immunogenic composition of claim 11, wherein the antigen of the PDCoV is a recombinant antigen comprising: (i) a PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28; and/or (ii) a polynucleotide encoding the PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28.

### Claim 14 (depends on 1)

A method for reducing a pig's risk for developing clinical signs of disease associated with PEDV, comprising administering to the pig the immunogenic composition according to claim 1.

### Claim 15 (depends on 11)

A method for reducing a pig's risk for developing clinical signs of disease associated with PEDV, comprising administering to the pig the immunogenic composition according to claim 11, and wherein the method reduces the pig's risk for developing clinical signs of disease associated with PEDV and PDCoV.

### Claim 16

A method for producing an immunogenic composition comprising a recombinant antigen of a PEDV and an adjuvant, comprising:
producing the recombinant antigen in a host cell;
harvesting the recombinant antigen from the host cell; and
adding an oil-in-water emulsion-based adjuvant to the recombinant antigen,
wherein the recombinant antigen comprises: (i) a PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53; and/or (ii) a polynucleotide encoding the PEDV spike protein having at least 90% sequence identity to SEQ ID NO:31, 35, 47 or 53.

### Claim 17 (depends on 16)

The method of claim 16, wherein the recombinant antigen comprises a PEDV spike protein expressed by a recombinant baculovirus vector.

### Claim 18 (depends on 17)

The method of claim 17, wherein the host cell is an insect cell.

### Claim 19

An immunogenic composition comprising an antigen of a PDCoV and an adjuvant, wherein the PDCoV comprises: (i) a polynucleotide having at least 99% sequence identity to SEQ ID NO: 2, 6, or 10; (ii) a polynucleotide having at least 99% sequence identity to a RNA complement of SEQ ID NO: 1, 5, or 9; and/or (iii) a spike protein encoded by a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 3, 7, 11, 17, or 27.

### Claim 20 (depends on 19)

The immunogenic composition of claim 19, wherein the antigen is:
an inactivated whole PDCoV; or
a recombinant antigen comprising: (i) a PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28; and/or (ii) a polynucleotide encoding the PDCoV spike protein having at least 90% sequence identity to SEQ ID NO: 4, 8, 12, 18, or 28.
